A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/13/2011	US20110250228 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
10/13/2011	US20110250211 Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
10/13/2011	US20110250204 Methods and compositions for diagnosing and treating diseases
10/13/2011	US20110250200 Soluble lymphotoxin-beta receptor fusion protein and methods for inhibiting lymphotoxin beta-receptor signaling
10/13/2011	US20110250197 Pharmaceutical combination
10/13/2011	US20110250194 Treatment with Anti-ErbB2 Antibodies
10/13/2011	US20110250193 Composition comprising expression or activity inhibitors of ninjurin1 for the prevention and treatment of inflammatory disease
10/13/2011	US20110250191 Composition for enhancing physical performance
10/13/2011	US20110250186 Methods for promoting wound healing and muscle regeneration with the cell signaling protein nell1
10/13/2011	US20110250179 Methods for treatment and diagnosis of cancer
10/13/2011	US20110250176 Combinations of Hepatitis C Virus Inhibitors
10/13/2011	US20110250175 Tlr7 ligand and uses thereof
10/13/2011	US20110250172 Hepatitis c virus inhibitors
10/13/2011	US20110250166 Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
10/13/2011	US20110250153 Oligomeric biosurfactants in dermatocosmetic compositions
10/13/2011	US20110250152 Anti-Microbial Dental Formulations for the Prevention and Treatment of Oral Mucosal Disease
10/13/2011	US20110250149 Tiotropium Bromide Having a Low Degree of Crystallinity
10/13/2011	US20110250147 Method and System for Reducing Skin Friction
10/13/2011	US20110250143 Process for preparing chlorins and their pharmaceutical uses
10/13/2011	US20110250142 Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
10/13/2011	US20110250139 Modified Pyrazine Derivatives and Uses Thereof
10/13/2011	US20110250137 Radioisotope-labeled lysine and ornithine derivatives, their use and processes for their preparation
10/13/2011	US20110250135 Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use
10/13/2011	US20110250134 Sustained release nitric oxide from long lived circulating nanoparticles
10/13/2011	US20110250132 Lipoic acid metabolite: useful for drug carrier, nanoparticle conjugate, imaging and hyperthermia therapy
10/13/2011	US20110250129 Bioluminescence imaging-based screening assay and inhibitors of abcg2
10/13/2011	US20110247613 Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
10/13/2011	DE102010014411A1 New iron complexes, useful as carbon monoxide and iron releasing molecules for treating e.g. high blood pressure, cancer, tissue damage by irradiation, post-ischemic injury, atherosclerosis, sepsis, angina and myocardial infarction
10/13/2011	DE102010014290A1 Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen Means for prophylactic and therapeutic treatment of herpes infections
10/13/2011	CA2832436A1 Controlled release pharmaceutical compositions of tapentadol
10/13/2011	CA2829790A1 Multisubstituted aromatic compounds as inhibitors of thrombin
10/13/2011	CA2800519A1 Biomarkers for mdm2 inhibitors for use in treating disease
10/13/2011	CA2796071A1 Ketorolac compositions for corneal wound healing
10/13/2011	CA2795877A1 Novel sultam compounds
10/13/2011	CA2795866A1 7,11-methanocycloocta [b] quinoline derivative as highly functionalizable acetylcholinesterase inhibitors
10/13/2011	CA2795765A1 Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
10/13/2011	CA2795750A1 Modulation of cetp expression
10/13/2011	CA2795732A1 Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
10/13/2011	CA2795729A1 Sophorolipid analog compositions
10/13/2011	CA2795726A1 Treatment of ataxia telangiectasia
10/13/2011	CA2795520A1 Methods and compositions for treating wounds utilizing chitosan compounds
10/13/2011	CA2795514A1 Novel hypoglycemic compounds
10/13/2011	CA2795513A1 Modulators of the gpr119 receptor and the treatment of disorders related thereto
10/13/2011	CA2795465A1 Pharmaceutical compositions highly dosed with biotin
10/13/2011	CA2795370A1 Radioprotector compounds and methods
10/13/2011	CA2795350A1 Ire-1.alpha. inhibitors
10/13/2011	CA2795334A1 Agent for prophylactic and therapeutic treatment of herpes infections
10/13/2011	CA2795322A1 Cephem compound having catechol group
10/13/2011	CA2795281A1 Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
10/13/2011	CA2795264A1 Glycomimetic compounds and methods to inhibit infection by hiv
10/13/2011	CA2795195A1 Thermally stable oil-in-water emulsions containing an oil that contains polyunsaturated fatty acids
10/13/2011	CA2795085A1 Indolyl or indolinyl hydroxamate compounds
10/13/2011	CA2794849A1 Methods and compositions for the treatment of irritable bowel syndrome
10/13/2011	CA2794801A1 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
10/13/2011	CA2794798A1 Treatment of gout
10/13/2011	CA2794566A1 Methods of using diacerein as an adjunctive therapy for diabetes
10/13/2011	CA2794565A1 Substituted androst-4-ene diones
10/13/2011	CA2794563A1 Gamma-polyglutamic acid-based ocular irrigating solutions
10/13/2011	CA2794252A1 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts
10/13/2011	CA2794112A1 Antimetastatic compounds
10/13/2011	CA2794096A1 Methods for treating respiratory viral infection
10/13/2011	CA2793951A1 Composition for amelioration of hypoalbuminemia
10/13/2011	CA2793900A1 Oxazole derivatives useful as modulators of faah
10/13/2011	CA2793730A1 Therapeutic agent or preventive agent for urine collection disorder
10/13/2011	CA2793709A1 Therapeutic agent or prophylactic agent for fibromyalgia
10/13/2011	CA2792942A1 Novel single chemical entities and methods for delivery of oligonucleotides
10/13/2011	CA2792561A1 Compositions and methods for inhibiting expression of cd274/pd-l1 gene
10/13/2011	CA2791324A1 Kinase inhibitors and method of treating cancer with same
10/13/2011	CA2791253A1 Polyol modified aminoglycoside-lipid conjugates
10/13/2011	CA2789818A1 Inverse agonists and neutral antagonists for the tsh receptor
10/13/2011	CA2788762A1 Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it
10/12/2011	EP2374885A2 ENA nucleic acid drugs modifying splicing in mRNA precursor
10/12/2011	EP2374884A2 Human miRNAs isolated from mesenchymal stem cells
10/12/2011	EP2374825A1 Photodynamic therapeutic agent showing accumulation of cell-specific functions
10/12/2011	EP2374814A2 Peptides that ellicit T cellular immunity
10/12/2011	EP2374807A2 An improved process for the isolation of temozolomide
10/12/2011	EP2374806A1 OXAZOLIDINON-QUINOLONe HYBRIDes and intermediates for their preparation
10/12/2011	EP2374805A1 Crystals of hydrochloride of pyridazin-3(2h)-one compound and process for production of same
10/12/2011	EP2374804A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
10/12/2011	EP2374802A1 Kynurenine production inhibitor
10/12/2011	EP2374798A1 Benzazepine derivatives useful as vasopressin antagonists
10/12/2011	EP2374797A1 Benzazepine derivatives useful as vasopressin antagonists
10/12/2011	EP2374796A1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders
10/12/2011	EP2374794A1 Cyclic amine compounds
10/12/2011	EP2374792A1 N-substituted benzene sulfonamides
10/12/2011	EP2374790A1 Biphenylacetamide derivative
10/12/2011	EP2374788A1 Indanyl compounds
10/12/2011	EP2374779A1 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
10/12/2011	EP2374479A2 Controlled-release composition for producing sustained-release preparation containing udenafil
10/12/2011	EP2374478A1 Nsaids-induced gastrointestinal mucosal disorder alleviator and manufacturing method thereof
10/12/2011	EP2374464A2 HCV N3S-NS4A protease inhibition
10/12/2011	EP2374462A2 Methods for controlling pests using RNAi
10/12/2011	EP2374461A1 Piroxicam for prophylactic and therapeutic treatment of herpes infections
10/12/2011	EP2374460A1 Pulsed-release sildenafil composition and method for preparing said composition
10/12/2011	EP2374459A1 Treatment for neurological and mental disorders
10/12/2011	EP2374458A1 Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS
10/12/2011	EP2374457A1 Antihypertensive pharmaceutical composition
10/12/2011	EP2374456A1 Activated blood coagulation factor x (fxa) inhibitor
10/12/2011	EP2374455A2 Modulators of muscarinic receptors
10/12/2011	EP2374454A1 Hemiasterlin derivatives and uses thereof in the treatment of cancer

1 ... 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 ... 7860